InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.065 -0.05 (-43.48%)+
Announcement
Release
13 Jan 2026 9:51AM
Price at Release
$0.115
Full Release
download
Summary
NeuroScientific Biopharmaceuticals Ltd (NSB) reported successful clinical results from their Special Access Program for patients with Fistulising Crohn's Disease treated with their StemSmart™ mesenchymal stem cell (MSC) therapy. Out of four patients treated, three showed a successful clinical response, and the fourth had a partial response. These results provide critical validation for the StemSmart platform and will guide future clinical trials, planned to commence in the second half of 2026. The program's success positions NSB to enter the large global market for Crohn's disease therapies and supports the broader application of StemSmart™ in other inflammatory conditions.
Key Points
  • Successful clinical results from patients with Fistulising Crohn's Disease treated with StemSmart™.
  • Three of four patients showed a successful clinical response.
  • Fourth patient had a partial response with ongoing assessments.
  • Results validate the StemSmart™ platform and inform future clinical trial design.
  • Phase 2 clinical trials planned for the second half of 2026.
  • StemSmart™ targets chronic inflammation in various conditions.
  • Potential entry into the US$13 billion global Crohn’s disease market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.